Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association

Carl E. Orringer, Terry A. Jacobson, Joseph J. Saseen, Alan S. Brown, Antonio M. Gotto, Joyce L. Ross, James A. Underberg

Research output: Contribution to journalArticlepeer-review

80 Scopus citations


An Expert Panel convened by the National Lipid Association was charged with updating the recommendations on the use of proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody therapy that were provided by the 2015 National Lipid Association Recommendations for the Patient-Centered Management of Dyslipidemia: Part 2. Recent studies have demonstrated the efficacy of these agents in reducing low-density lipoprotein cholesterol and non–high-density lipoprotein cholesterol and have confirmed their excellent safety profile. A cardiovascular outcomes study has shown that these agents reduce incident atherosclerotic cardiovascular disease (ASCVD) events in patents with stable ASCVD and concomitant risk factors. The current update provides the Expert Panel's evidence-based recommendations on the clinical utility of PCSK9 inhibitors in patients with stable ASCVD, progressive ASCVD, LDL-C ≥ 190 mg/dL (including polygenic hypercholesterolemia, heterozygous familial hypercholesterolemia and the homozygous familial hypercholesterolemia phenotype) and very-high-risk patients with statin intolerance.

Original languageEnglish (US)
Pages (from-to)880-890
Number of pages11
JournalJournal of Clinical Lipidology
Issue number4
StatePublished - Jul 2017


  • Alirocumab
  • Dyslipidemia
  • Evolocumab
  • Familial hypercholesterolemia
  • Hypercholesterolemia
  • Lipid treatment guidelines
  • PCSK9 inhibitors
  • Statin intolerance

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association'. Together they form a unique fingerprint.

Cite this